RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Stay focused on the facts https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3201164/
Here's a paper that compares Trop2 expression in normal cells versus cancer cells. It's the target for Trodelvy that Gilead paid $21 billion for and did nearly $400 million in sales last year on it's so far very limited label. If you read that paper, which I assume somebody at Gilead did, you might wonder how it ever got approved. That paper says the Trop2 protein is expressed in some normal tissue at least as highly as in tumour cells. This is potentially an obvious source of off-target toxicity. This drug comes with a black box warning but is still used by clinicians.
Another ADC Padcev had close to 50% of it's patients experience peripheral neuropathy and 50% had ocular problems. Both were mostly low grade and manageable but there are instructions to discontinue this drug for grade 3 or higher.
These are the circumstances and profiles of approved drugs. This is the ballpark th1902 will hopefully be playing in. Spatrap can make the calls he chooses to make. I just don't think I have enough info to do that yet. For me we are still mostly in the dark.